Several possible studies
Story checked
DEBRA research invests in Topadur to advance small-molecule therapies for dystrophic Epidermolysis bullosa (opens in a new tab)
news-medical.net · 2026-10-28
Short answer
Several possible studiesStudy not confirmed.
Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
The story
DEBRA research invests in Topadur to advance small-molecule therapies for dystrophic Epidermolysis bullosa
news-medical.net · 2026-10-28
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Multiple potential source studies identified.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
View article claimsSearch result
Several studies could fit.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
Evidence layer
Claim by claim
The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 5Not checkedDEBRA Research is investing in Topadur to support a preclinical program exploring a new treatment approach for dystrophic epidermolysis bullosa.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 2 of 5Not checkedThe program will evaluate Topadur’s clinical-stage compound TOP-N53 together with additional selected small molecules from its DualTOP platform in in vitro and in vivo models addressing impaired wound healing and fibrosis in DEB.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 3 of 5Not checkedThe studies will be conducted in collaboration with the Medical Center – University of Freiburg and EB Research Institute GmbH in Salzburg.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 4 of 5Not checkedTOP-N53 has demonstrated wound-healing activity in preclinical models and increased local skin perfusion in a first-in-human Phase 1 study, where it was well tolerated.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 5 of 5Not checkedTOP-N53 is currently in Phase 2a clinical development for digital ulcers in systemic sclerosis and has received Orphan Drug Designation from both the FDA and EMA.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Method layer
Study not confirmed.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
PubMed, Crossref · 15 candidate papers
Formulation and dermal delivery of a new active pharmaceutical ingredient in an in vitro wound model for the treatment of chronic ulcers.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik e.V · 2024 · PubMed
EPIDERMOLYSIS BULLOSA
Wound Healing · 2005 · Crossref
Dual-Acting Nitric Oxide Donor and Phosphodiesterase Inhibitor TOP-N53 Increases Lifespan and Health Span of Caenorhabditis elegans.
microPublication Biology · 2024 · PubMed
Topical Wound Treatment with a Nitric Oxide-Releasing PDE5 Inhibitor Formulation Enhances Blood Perfusion and Promotes Healing in Mice.
Pharmaceutics · 2022 · PubMed
ISID1517 - Natural history of spontaneous wound healing in recessive dystrophic epidermolysis bullosa wound types using a mobile photography application
2023 · Crossref